Sjogrens

Have you heard of nipocalimab? It prevents IgG-FcRn by binding to the FcRn IgG binding site. This is one to watch in our diseases (RA, Sjogren’s, SLE, myopathies.) Dr. Postolova #RWCS23 ⁦@RheumNow⁩ ⁦@RWCSmtg⁩ https://t.co/qMGA6IdtUE
Dr. Rachel Tate @uptoTate( View Tweet )
Feb 16, 2023
Low Dose IL-2 Therapy in Sjögren’s There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that lLD-IL-2 was effective and well tolerated in patients with pSS, with evidence of restored immune balance. https… https://t.co/r0AlTD45gG
Dr. John Cush @RheumNow( View Tweet )
Dec 04, 2022
230px-Sjogren_syndrome_%282%29.jpg

Low Dose IL-2 Therapy in Sjögren’s

Jack Cush, MD
Nov 29, 2022

There is a large, unmet need in treating Sjögren’s syndrome, yet a new randomized clinical trial has shown that low-dose interleukin 2 (LD-IL-2) was effective effective and well tolerated in patients with primary Sjögren’s syndrome (pSS), with evidence of restored immune balance.

Read Article
Potential new treatment for Sjogren's Is there finally something new on the horizon in Sjogren’s syndrome? Dr. Eric Dein. ( @ericdeinmd) discusses studies presented at #ACR22. https://t.co/YinEPKlJb2 https://t.co/YOsc159GFt

Links:

Dr. John Cush @RheumNow( View Tweet )
Nov 26, 2022
#ACR22 Abstr#2033 How negative is sero-ve #Sjogren? A study discovered new autoantibodies using Peptidome Array Technology. AUC for these 8 peptides was excellent 0.97. Mainly in White/Hispanic. Need validation in other groups and association with other markers/biopsy @RheumNow https://t.co/xAFrjK9mS3
Md Yuzaiful Md Yusof @Yuz6Yusof( View Tweet )
Nov 14, 2022
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow

Dr. Antoni Chan @synovialjoints( View Tweet )

Nov 13, 2022
Dörner et al. Remibrutinib (BTKi) in pSS. + study in pSS! Improved ESSDAI (disease activity), no effect ESSPRI (PRO), trend to improve salivary flow, + effect on multiple labs. @RheumNow #ACR22 Abstr#1113 https://t.co/m2rvXbqq7b https://t.co/jQLyP66zX9

Links:

Richard Conway @RichardPAConway( View Tweet )
Nov 13, 2022
Pike M Abstract 1113. Remibrutinib (LOU064) in Sjögren’s Syndrome: Safety and Efficacy Results from a 24‑Week Placebo-controlled Proof-of-Concept Study #ACRBest #ACR22 @RheumNow

Dr. Antoni Chan @synovialjoints( View Tweet )

Nov 13, 2022
Fulvio et al. Labial gland US to identify lymphoma in Sjogrens. OMERACT score of 3 in 100% of lymphoma and 35% non-lymphoma @RheumNow #ACR22 Abstr#1254 https://t.co/aspctOfGp8 https://t.co/CLhN2PTvaS

Links:

Richard Conway @RichardPAConway( View Tweet )
Nov 13, 2022
Plenary: Remibrutinib (LOU064) a BTK inhibitor in Sjogren’s ◦ Favourable safety profile ◦ Well-tolerated over 24 Wks ◦ Improved ESSDAI, salivary flow, Igs ◦ May be first effective oral disease-modifying therapy for SS Dorner T Abs1113 https://t.co/FkgJpwKAJL #ACR22 @RheumNow https://t.co/znxMc27EBI

Links:

Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 13, 2022
light-bulbs-1125016_640.jpg

Potential new treatment for Sjogren's

Eric Dein, MD
Nov 13, 2022

Is there finally something new on the horizon in Sjogren’s syndrome? 



At the second plenary session, Dr. Thomas Dorner presented abstract 1113 on a medication that may at long last be a disease modifying agent. Remibrutinib (LOU064) is a highly specific inhibitor of Bruton’s tyrosine

Read Article
Sjogren’s is tough to study, isn’t it? LOUiSSe (remibrutinib proof-of-concept SjS) - benefit with: - ESSDAI (primary, obj dx activity) ✅ - auto-Ab ✅ - all patient outcomes ❎ Has already exceeded many attempts Even then, still some limitations ABST1113 #ACR22 @RheumNow https://t.co/NlBaFVuuPa
David Liew @drdavidliew( View Tweet )
Nov 13, 2022
Ab1113 #ACR22 Remibrutinib (LOU064, BTK inhib) in Sjogren's Will there be new Rx for Sjo? T Dorner: 73 pts Ph2 BTK 100mg BID/100 QD/PBO Better ESSDAI at wk 24 (p=0.003) Unstim saliv flow: improved vs PBO, not stat signif Decreased CXCL13 chemokine PROs not improved @RheumNow https://t.co/hJp33JPpHt
Eric Dein @ericdeinmd( View Tweet )
Nov 13, 2022
Sjogren's in a Plenary! Remibrutinib (BTKi) in SjS Improved ESSDAI at wk 24, but NONE on ESSPRI (more patient-centric ie fatigue, dryness, joint pain) Definitely helps w/lab abnormalities, but worried benefit for outcomes that matter may be limited #ACR22 @RheumNow abstr#1113 https://t.co/GutY8KndbR
Mike Putman @EBRheum( View Tweet )
Nov 13, 2022
Initial Remibrutinib (oral, covalent, and highly specific inhibitor of Bruton’s tyrosine kinase (BTK)) data in SS shows good efficacy and safety. Plenary Abs 1113 #ACR22 @RheumNow https://t.co/5Zr0Y1ueAv https://t.co/Iy194YUWNC

Links:

Dr. Rachel Tate @uptoTate( View Tweet )
Nov 13, 2022
2nd Plenary Session! Remibrutinib (BTK inhibitor) for treatment of Sjögren's syndrome (phase 2 study) Improvement of ESSDAI, salivary flow and pathologically elevated Ig's Abs#1113 @RheumNow #ACR22 https://t.co/vdgxBPe6qd
Robert B Chao, MD @doctorRBC( View Tweet )
Nov 13, 2022
Mimics of Sjogren’s Syndrome @RheumNow #ACR22 https://t.co/nEAXKb6qF0
Dr. Antoni Chan @synovialjoints( View Tweet )
Nov 12, 2022
Low dose IL-2 works in Primary Sjogrens Syndr (pSS)? RCT 60 pSS pts rx w/ PBO vs LD-IL-2; latter lower ESSDAI @wk 24 (67% vs 27%; P=.004) & less Sxs (dryness,fatigue) @wk12 and expansion of TREGs & CD24highCD27+ B cells. https://t.co/39U6WX7ceM https://t.co/i56XDSvGXs

Links:

Dr. John Cush @RheumNow( View Tweet )
Nov 11, 2022
Here's a nice slide comparing Sjogren's disease and Sarcoidosis: #ACR22 @RheumNow #acrreview #MedTwitter https://t.co/MQQx3GBl5f
sheila @RHEUMarampa( View Tweet )
Nov 11, 2022
Sialadenosis is a mimic of #sjogren - it related to fatty infiltration/metabolic syndrome. Correct underlying issue and pts will improve - Dr S McCoy @rheumnow #acrreview #acr22 https://t.co/bZPj1LmERs
TheDaoIndex @KDAO2011( View Tweet )
Nov 11, 2022
Wonderful slide by Dr. Sarah McCoy on #Sjogrens #ACR22 @RheumNow Broad differential for these patients when they present in clinic: 📍Ask about: 🚬 habits 💊 meds 🍬 🩻history: #diabetes, past radiation exposure 🦠 infection (#HIV, #HCV) 🩸 #vitamin deficiency https://t.co/6Qo23lWBs4
Catherine Sims, MD @DrCassySims( View Tweet )
Nov 11, 2022
Sjogrens - Dx tips, myths & mistakes: • SS not rare; affects 1 in 400 • 95% female, but SS is more severe in men • African Americans have a severe systemic phenotype • Asians report dryness Sxs • Smoking & alcohol intake often avoided by SS pts https://t.co/B2hR7z8H5Z https://t.co/g0FKhcmoXa

Links:

Dr. John Cush @RheumNow( View Tweet )
Oct 12, 2022
Multicentre matched control study looked at primary Sjogrens that developed lymphoma or NOT. Parotid swelling (PSW) is an early major predictor of non-Hodgkin lymphoma in pSS; esp if present before or dx, & w/ a longer duration of PSW https://t.co/QokXF6klEv https://t.co/YqFgAqt4ku

Links:

Dr. John Cush @RheumNow( View Tweet )
Sep 06, 2022
mitochondrial,DNA

Mitochondria as Master Regulators of Inflammation

Jack Cush, MD
Jul 25, 2022

Mitochondrial constituents and metabolic products may give rise to immune activation; this is especially true for mitochondrial DNA, which can function as damage-associated molecular patterns (DAMPs) leading to inflammasome activation.



DAMPs and pathogen-associated molecular patterns

Read Article
🌏 Today is World Sjögren's Day!🌍 🩺 Sjögren's is not Just Dry eyes👁️ and Dry Mouth👅👄 - there's much more to it There's still a lot about this 'invisible' #Autoimmune Disorder, we don't know Clinical Features and Pathogenesis #LetstalkaboutSjögrens #MedTwitter #RheumTwitter https://t.co/t9toed8MG7
EnvisionRheumat @ERheumat( View Tweet )
Jul 25, 2022

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2023 All Rights Reserved.

×